Clinical Trials Logo

Leishmaniasis, Cutaneous clinical trials

View clinical trials related to Leishmaniasis, Cutaneous.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06011343 Not yet recruiting - Clinical trials for Cutaneous Leishmaniasis, American

Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis

CLTofa23
Start date: October 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

Phase 2/3 randomized and controlled clinical trial, which will evaluate the effectiveness of the association meglumine antimoniate (Glucantime) with tofacitinib in the cure of CL and the capacity of this association to reduce the time of cure of the disease.

NCT ID: NCT05493059 Not yet recruiting - Primary Health Care Clinical Trials

Study of Cases of Cutaneous Leishmaniasis Treated With Miltefosine in French Guiana, Retrospective Study

MILT2022
Start date: August 8, 2022
Phase:
Study type: Observational

Miltefosine is the only oral treatment currently available for Cutaneous Leishmaniasis. Despite several reports of good efficiency in other countries of South America, miltefosine remains limited to a compassionate use in France. The objective of this study is to collect data regarding the efficacy, safety and acceptability of miltefosine in patients treated in French Guiana since 2017.

NCT ID: NCT04268524 Not yet recruiting - Clinical trials for Old World Cutaneous Leishmaniasis

Randomised Clinical Trial for New Treatment Modalities for Cutaneous Leishmaniasis Caused by Leishmania Tropica, in Pakistan

Start date: February 1, 2021
Phase: Phase 3
Study type: Interventional

randomised control clinical trial to evaluate miltefosine, thermotherapy and the combination miltefosine-thermotherapy are effective, safe and tolerable alternative treatment options to treat cutaneous leishmaniasis caused by L. tropica, in Pakistan compared to the standard of care.

NCT ID: NCT03084952 Not yet recruiting - Drug Side Effect Clinical Trials

Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients

Start date: May 2021
Phase: Phase 2
Study type: Interventional

It is a randomized phase II clinical study, unicentre aimed to evaluate the tolerability, safety and efficacy of 18-Methoxyoronaridine as a candidate of tegumentary leishmaniasis treatment.

NCT ID: NCT02281669 Not yet recruiting - Clinical trials for Cutaneous Leishmaniasis

Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients

Start date: November 2014
Phase: N/A
Study type: Observational

Cutaneous leishmaniasis (CL) is endemic in Israel and is caused by Leishmania major or Leishmania tropica. CL is usually a benign disease and limited to the skin. One of the local treatment available is intralesional (IL) Pentostam injection. During the current study the investigators will monitor the adverse effects of this treatment and will follow up the recovery of the lesions after Pentostam injections.